Association Between Postoperative Administration of L-Arginine and CSA-AKI

NCT ID: NCT06248359

Last Updated: 2025-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

7000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-12-01

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To investigate the association between the the early administration of L-Arginine after CPB-assisted cardiac surgery and the incidence of CS-AKI in adult patients. To test if it can reduce the incidence of post-operative AKI.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arginine Use

At least one dose of L-arginie was administered in the early postoperative stage

L-Arginine hydrochloride

Intervention Type DRUG

Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI

Without Arginine

No L-arginie was administered

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-Arginine hydrochloride

Postoperative administration of L-Arginine hydrochloride before incidence of CS-AKI

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult patients (over 18 years)
* underwent CPB assisted cardiac surgery
* admitted to ICU

Exclusion Criteria

* congenital heart disease
* underwent deep hypothermic circulatory arrest (DHCA)
* with glomerular filtration rate (eGFR) below 30 mL/min/1.73 m²
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xijing Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chong Lei, MD & phD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chong Lei

Role: PRINCIPAL_INVESTIGATOR

Xijing Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xijing Hospital

Xi'an, Shaanxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ziyu Zheng

Role: CONTACT

+86-13228082320

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chong Lei, MD & phD

Role: primary

86-18629011362

lini Wang, MD

Role: backup

86-15209234508

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KY20232170-C-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.